Heterogeneity in HER2 and fibroblast growth factor receptor 2 (FGFR2) overexpressing cells in fresh tumour tissue was shown to be retained in PDOs [44], although differences in HER2 expression between primary tumour and PDOs have been reported as well [45]. The gene discussed is FGFR2; the disease is neoplasm.